Ruchaud, S. | IICIMED

P285

Int. J. Pharm. Res. Al. Sci. 2024, 13, 1-11.

Design and synthesis of functionalized 2,4-diamino-1,3,5-triazines, potential inhibitors involved in immune and inflammatory response.

https://doi.org/10.51847/hsT2C61XWx

P202

Pharmaceuticals 2019, 12, 169.

Biological evaluation of arylsemicarbazone derivatives as potential anticancer agents.

doi:10.3390/ph12040169

P178

Eur. J. Med. Chem. 2018, 154, 101-109.

Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.

doi: 10.1016/j.ejmech.2018.04.056

P177

Bioorg. Med. Chem. 2018, 26, 4209-4224.

Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.

doi: 10.1016/j.bmc.2018.07.012.

P173

Bioorg. Med. Chem. Lett. 2018, 28, 2250-2255.

Benzofuro[3,2-d]pyrimidines inspired from cercosporamide CaPkc1 inhibitor: synthesis and evaluation of fluconazole susceptibility restoration.

doi: 10.1016/j.bmcl.2018.05.044

P155

Anticancer Res. 2016, 36, 1621-1630.

Discovery of (imidazo[1,2-a]pyrazin-6-yl)ureas as antiproliferative agents targeting P53 in non-small cell lung cancer cell lines.

P142

Eur. J. Med. Chem. 2015, 105, 80-105.

Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii Calcium-Dependent Protein Kinase 1.

doi: 10.1016/j.ejmech.2015.10.004

P136

Eur. J. Med. Chem. 2015, 103, 381-395.

Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.

doi: 10.1016/j.ejmech.2015.09.002

P108

Eur. J. Med. Chem., 2012, 58, 543-556.

Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.

P106

J. Med. Chem., 2012, 57, 225-233.

Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K inhibitors. Eur.